WO2006015191A3 - Multicyclic lonidamine analogs - Google Patents

Multicyclic lonidamine analogs Download PDF

Info

Publication number
WO2006015191A3
WO2006015191A3 PCT/US2005/026929 US2005026929W WO2006015191A3 WO 2006015191 A3 WO2006015191 A3 WO 2006015191A3 US 2005026929 W US2005026929 W US 2005026929W WO 2006015191 A3 WO2006015191 A3 WO 2006015191A3
Authority
WO
WIPO (PCT)
Prior art keywords
multicyclic
lonidamine analogs
lonidamine
analogs
bph
Prior art date
Application number
PCT/US2005/026929
Other languages
French (fr)
Other versions
WO2006015191A2 (en
Inventor
Mark Matteucci
Photon Rao
Jian-Xin Duan
Original Assignee
Threshold Pharmaceuticals Inc
Mark Matteucci
Photon Rao
Jian-Xin Duan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc, Mark Matteucci, Photon Rao, Jian-Xin Duan filed Critical Threshold Pharmaceuticals Inc
Publication of WO2006015191A2 publication Critical patent/WO2006015191A2/en
Publication of WO2006015191A3 publication Critical patent/WO2006015191A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

The invention provides lonidamine analogs as well as methods of treating cancer and BPH.
PCT/US2005/026929 2004-07-29 2005-07-29 Multicyclic lonidamine analogs WO2006015191A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US59267704P 2004-07-29 2004-07-29
US60/592,677 2004-07-29
US59966404P 2004-08-05 2004-08-05
US60/599,664 2004-08-05
US65167105P 2005-02-09 2005-02-09
US60/651,671 2005-02-09

Publications (2)

Publication Number Publication Date
WO2006015191A2 WO2006015191A2 (en) 2006-02-09
WO2006015191A3 true WO2006015191A3 (en) 2006-11-09

Family

ID=35787857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026929 WO2006015191A2 (en) 2004-07-29 2005-07-29 Multicyclic lonidamine analogs

Country Status (2)

Country Link
TW (1) TW200605885A (en)
WO (1) WO2006015191A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5180824B2 (en) 2005-06-29 2013-04-10 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド Phosphoramidate alkylating agent prodrug
WO2007139499A1 (en) * 2006-05-31 2007-12-06 Aprea Ab Compounds for use as a medicament
UA105039C2 (en) 2009-02-24 2014-04-10 Мерк Шарп Енд Доме Корп. Indole derivatives as crth2 receptor antagonists
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
CN102786463B (en) * 2012-07-02 2013-12-18 浙江金伯士药业有限公司 Method for preparing 5-acetoxyl-3-indole carboxylic acid ethyl ester
CN108659003B (en) * 2018-04-14 2021-01-26 上海朝晖药业有限公司 Preparation method of compound for treating oral ulcer
EP3564214A1 (en) 2018-05-04 2019-11-06 Universita' Degli Studi G. D Annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
CN108440538B (en) * 2018-05-04 2021-03-16 上海工程技术大学 Novel pyrroloimidazole derivative and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2006015191A2 (en) 2006-02-09
TW200605885A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2006015263A3 (en) Lonidamine analogs
WO2007059041A3 (en) Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2007053573A3 (en) Treatment of cancer with sorafenib
EP2671581B8 (en) Compositions and methods for treating cancer
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008013589A3 (en) Treatment of ras-expressing tumors
TW200732349A (en) Anti-OX40L antibodies and methods using same
EP1667680A4 (en) Combination methods of treating cancer
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007044026A3 (en) Compositions comprising modified collagen and uses therefore
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
EP1613308A4 (en) Novel methods for the treatment of cancer
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
WO2006130429A3 (en) Treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2004048551A3 (en) Target for therapy of cognitive impairment
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005110479A3 (en) Treatments for pancreatic cancer
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase